Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after
ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates …

Recombinant tissue‐type plasminogen activator (rt‐PA) is presently the only
pharmacological treatment approved for thrombolysis in patients suffering from ischemic …

Recombinant tissue plasminogen activator (rt-PA) is the only pharmacological treatment
approved for thrombolysis in patients suffering from ischemic stroke, but its administration …

Focal cerebral ischemia activates the nuclear protein poly (ADP-ribose) polymerase (PARP)
by single DNA strand breaks which leads to energy depletion and cell necrosis. Deletion or …

Hemorrhagic transformation is an aggravating event that occurs in 15 to 43% of patients
suffering from ischemic stroke. This phenomenon due to blood-brain barrier breakdown …

In patients with stroke and neurodegenerative diseases, overactivation of poly (ADP-ribose)
polymerase-1 (PARP-1) causes harmful effects by inducing apoptosis, necrosis …

Background and Purpose—Most stroke patients do not present for medical treatment until
several hours after onset of brain ischemia. Consequently, neuroprotective strategies are …

Overactivation of poly (ADP-ribose) polymerase-1 (PARP-1) in response to DNA damage is
considered to play a crucial role in the development of post-ischemic neuronal injury, such …

Recombinant tissue plasminogen activator (rt‐PA) treatment improves functional outcome
after acute ischemic stroke, inducing reperfusion by its thrombolytic activity. Conversely …

Cerebral ischemia induces excessive activation of poly (ADP-ribose) polymerase-1 (PARP-
1), leading to neuronal cell death and the development of post-ischemic dysfunction …